This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Divalproex sodium

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20230921

Version

8

Spl Product Data Elements

divalproex sodium divalproex sodium DIVALPROEX SODIUM VALPROIC ACID ALCOHOL AMMONIA BUTYL ALCOHOL CELLULOSE, MICROCRYSTALLINE FD&C BLUE NO. 1 FERROSOFERRIC OXIDE GELATIN HYPROMELLOSES ISOPROPYL ALCOHOL METHACRYLIC ACID POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC SILICON DIOXIDE SODIUM LAURYL SULFATE TALC TITANIUM DIOXIDE TRIETHYL CITRATE WATER BLUE WHITE CAPSULE ZA66;125mg

Application Number

ANDA078919

Brand Name

Divalproex sodium

Generic Name

divalproex sodium

Product Ndc

65841-639

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-639-01 in bottle of 100 Capsules Divalproex sodium delayed-release capsules, USP (sprinkle) Rx only 100 capsules Divalproex Sodium Capsules Sprinkle, 125 mg

Spl Medguide

SPL MEDGUIDE

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.